Dear Robert: One bit of feedback – I learned from one of your interviews that DHA
reduces dyskinesias. I have now tried that option and my dyskinesias are markedly improved.
The last few days have been a whirlwind. I have suddenly found my feet and my standing and walking feel completely different. I would say I have 40% greater range of moment when I do my stretches and can easily balance on one leg in the morning before I take my first dose. I have had to space my drug doses out and don’t have time to take all the meds in the day – the dose lasts much longer.
The downside is I have far too much Sinemet in my system and the dyskinesia is back. I’m not sure what to do but will be very careful. Neurologists here don’t understand the concept of feeling better unless it is due to some drug they have prescribed. I will have a good sleep and see what the morning brings. It is an amazing experience to stand on my legs and feel grounded again.
Circumstances have arisen which has caused me to accept a loss related to my birth family. This wasn’t something I knew I was battling with but out of the blue things fell into place. I wonder if this has prompted the change.
With all good wishes,
Fiona
Below is a study that presents evidence that confirms and supports Fionas experience that DHA reduces dyskinesias.
Robert Rodgers PhD
Founder 2004
Parkinsons Recovery
Int J Mol Sci. 2023 Jun 27;24(13):10717. DHA/EPA (Omega-3) and LA/GLA (Omega-6) as Bioactive Molecules in Neurodegenerative Diseases
Abstract
Neurodegenerative diseases are characterized by neuroinflammation, neuronal depletion and oxidative stress. They coincide with subtle chronic or flaring inflammation, sometimes escalating with infiltrations of the immune system cells in the inflamed parts causing mild to severe or even lethal damage. Thus, neurodegenerative diseases show all features of autoimmune diseases.
Prevalence of neurodegenerative diseases has dramatically increased in recent decades and unfortunately, the therapeutic efficacy and safety profile of available drugs is moderate. The beneficial effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) polyunsaturated fatty acids (omega-3 PUFAs) are nowadays highlighted by a plethora of studies. They play a role in suppression of inflammation, gene expression, cellular membrane fluidity/permeability, immune functionality and intracellular/exocellular signaling.
The role of omega-6 polyunsaturated fatty acids, such as linoleic acid (LA), gamma linolenic acid (GLA), and arachidonic acid (AA), on neuroprotection is controversial, as some of these agents, specifically AA, are proinflammatory, whilst current data suggest that they may have neuroprotective properties as well.
This review provides an overview of the existing recent clinical studies with respect to the role of omega-3 and omega-6 PUFAs as therapeutic agents in chronic, inflammatory, autoimmune neurodegenerative diseases.